Literature DB >> 18978464

Somatic mosaicism in primary immune deficiencies.

Taizo Wada1, Fabio Candotti.   

Abstract

PURPOSE OF REVIEW: Spontaneous genetic reversions and second-site mutations resulting in revertant somatic mosaicism are poorly understood phenomena with a seemingly frequent occurrence in primary immunodeficiency diseases. Here we summarize the several cases that have been reported thus far with particular focus on the most recent observations. RECENT
FINDINGS: Revertant cells have been associated with attenuated clinical phenotypes in some, although not all, immunodeficient patients who presented with somatic mosaicism. Interestingly, the latest studies suggest that revertant cells may also be responsible for immune dysregulation. In addition, extensive molecular analysis of revertant cells has revealed that an unexpectedly large variety of genetic changes can be responsible for their emergence.
SUMMARY: The occurrence of revertant somatic mosaicism in patients affected with primary immunodeficiency diseases is likely much more common than originally anticipated. The study of this fascinating phenomenon continues to provide clues as to the possible underlying mechanisms and to inform, albeit indirectly, the process of development of cell and gene therapy for these diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18978464     DOI: 10.1097/ACI.0b013e328314b651

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  32 in total

Review 1.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

2.  Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.

Authors:  M Moncada-Vélez; A Vélez-Ortega; J Orrego; I Santisteban; J Jagadeesh; M Olivares; N Olaya; M Hershfield; F Candotti; J Franco
Journal:  Scand J Immunol       Date:  2011-11       Impact factor: 3.487

Review 3.  Gene therapy using haematopoietic stem and progenitor cells.

Authors:  Giuliana Ferrari; Adrian J Thrasher; Alessandro Aiuti
Journal:  Nat Rev Genet       Date:  2020-12-10       Impact factor: 53.242

Review 4.  Human hyper-IgE syndrome: singular or plural?

Authors:  Qian Zhang; Bertrand Boisson; Vivien Béziat; Anne Puel; Jean-Laurent Casanova
Journal:  Mamm Genome       Date:  2018-08-09       Impact factor: 2.957

5.  RAG1 reversion mosaicism in a patient with Omenn syndrome.

Authors:  Elena Crestani; Sharon Choo; Francesco Frugoni; Yu Nee Lee; Stephanie Richards; Joanne Smart; Luigi D Notarangelo
Journal:  J Clin Immunol       Date:  2014-05-10       Impact factor: 8.317

6.  Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency.

Authors:  Sebastian Fuchs; Anne Rensing-Ehl; Ulrich Pannicke; Myriam R Lorenz; Paul Fisch; Yogesh Jeelall; Jan Rohr; Carsten Speckmann; Thomas Vraetz; Susan Farmand; Annette Schmitt-Graeff; Marcus Krüger; Brigitte Strahm; Philipp Henneke; Anselm Enders; Keisuke Horikawa; Christopher Goodnow; Klaus Schwarz; Stephan Ehl
Journal:  Blood       Date:  2015-08-19       Impact factor: 22.113

Review 7.  Genetics of SCID.

Authors:  Fausto Cossu
Journal:  Ital J Pediatr       Date:  2010-11-15       Impact factor: 2.638

Review 8.  Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy.

Authors:  Perry B Hackett; David A Largaespada; Kirsten C Switzer; Laurence J N Cooper
Journal:  Transl Res       Date:  2013-01-10       Impact factor: 7.012

9.  Extensive genetic variation in somatic human tissues.

Authors:  Maeve O'Huallachain; Konrad J Karczewski; Sherman M Weissman; Alexander Eckehart Urban; Michael P Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-05       Impact factor: 11.205

Review 10.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.